Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Treatment withdrawal in relapsing-remitting multiple sclerosis: a retrospective cohort study.
Microglia in health and disease.
Clinical Characteristics of Pediatric-Onset and Adult-Onset Multiple Sclerosis in Hispanic Americans.
Brain reserve against physical disability progression over 5 years in multiple sclerosis.
The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis.
Teriflunomide modest help but safe for MS
Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.
Extracellular Cues Influencing Oligodendrocyte Differentiation and (Re)myelination.
Teva Receives Positive Outcome in Europe for Three-Times-a-Week COPAXONE® (Glatiramer Acetate) 40 mg/ml for the Treatment of Relapsing Forms of Multiple Sclerosis (RMS)
Biogen Data at 2016 AAN Annual Meeting Highlight Its Expansive Portfolio of MS Therapies That Meets Diverse Needs of Patients
Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β.
Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID).
Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.
Serum IL-33 levels and skin mRNA expression in Behçet's disease.
Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis.
Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.
The MS Microbiome Consortium (MSMC): an academic multi-disciplinary collaborative effort to elucidate the role of the gut microbiota in MS
New diagnostic criteria for multiple sclerosis: guidelines for research protocols.
Long-Term Effects of Exposure to Disease-Modifying Drugs in the Offspring of Mothers with Multiple Sclerosis: A Retrospective Chart Review.
GlaxoSmithKline Product Development Pipeline
Masitinib in Patients with Primary Progressive Multiple Sclerosis (PPMS) or Relapse-Free Secondary Multiple Sclerosis (SPMS)
Optical coherence tomography should be part of the routine monitoring of patients with multiple sclerosis: Yes.
Multiple sclerosis in Hispanics: a study of clinical disease expression.
The differential diagnosis of neurological diseases by fractionating electrophoretically the CSF gamma-globulins.
The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail?
Pages
« first
‹ previous
…
20
21
22
23
24
25
26
27
28
…
next ›
last »